An assessment of age and other factors influencing protocol versus alternative treatments for patients with epithelial ovarian cancer referred to member institutions: a Gynecologic Oncology Group study.
An assessment of age and other factors influencing protocol versus alternative treatments for patients with epithelial ovarian cancer referred to member institutions: a Gynecologic Oncology Group study.
复制标题
对上皮性卵巢癌患者的年龄和其他影响方案与替代治疗的影响因素的评估参考了成员机构：一项妇科肿瘤小组研究。
DOI：
10.1016/j.ygyno.2004.05.033
复制
发表时间：
2004
期刊：
影响因子：
--
通讯作者：
VanLe,Linda
中科院分区：
文献类型：
--
作者：
Moore,DavidH;Kauderer,JamesT;Bell,Jeffrey;Curtin,JohnP;VanLe,Linda
目的评估上皮性卵巢癌患者参加妇科肿瘤组(GOG)前瞻性治疗研究的频率，以及患者年龄或其他因素对入选的影响。符合条件的患者提供书面知情同意，同意将人口统计和医疗记录数据提交给方案数据库进行分析。病理诊断经中心复习证实。收集人口学和临床数据，包括并存的医疗条件、肿瘤分期、分级和组织学、外科操作、计划的术后治疗以及患者未按GOG方案治疗的原因/S(如果适用)。随后，137名(15%)患者根据病理(低恶性潜能肿瘤)被排除在外，还有10名患者的侵袭性疾病没有分期。在符合条件的801例患者中，36%为65岁的≥患者，52%为乳头状浆液性肿瘤，73%为III/IV期疾病。在65岁的患者中，67%的患者处于III/IV期，而65岁的患者≥的这一比例为82%。III/IV期患者的平均年龄比I/II期患者高5.5岁。与年轻患者相比，患有III/IV期疾病的老年患者不太可能进入GOG治疗方案。最常见的原因是患者不合格(33%)、拒绝(29%)和研究人员决定(20%)。结论年龄似乎是影响III/IV期卵巢癌患者治疗选择的重要因素。除了审查资格标准外，还应监测从业者的态度，以确保老年患者不会被不适当地拒绝参加GOG临床试验。
ObjectiveTo assess the frequency with which patients with epithelial ovarian cancer are enrolled in prospective Gynecologic Oncology Group (GOG) treatment studies and to assess whether enrollment is influenced by patient age or other factors.MethodsThe study was open to patients with primary, previously untreated epithelial ovarian cancer referred to member institutions. Eligible patients provided written informed consent to have demographic and medical records data submitted to the protocol database for analysis. Pathologic diagnosis was confirmed by central review. Demographic and clinical data, including coexisting medical conditions, tumor stage, grade, and histology, surgical procedures, planned postoperative therapy, and reason/s (if applicable) a patient was not treated per GOG protocol, were collected.ResultsNine hundred and forty-eight patients were initially eligible. Subsequently, 137 (15%) patients were excluded based on pathology (low malignant potential tumors), as were 10 whose invasive disease was unstaged. Among 801 eligible patients, 36% were ≥65 years of age, 52% had papillary serous tumors, and 73% had stage III/IV disease. In patients aged <65 years, 67% were stage III/IV compared to 82% of patients ≥65 years of age. The mean age was 5.5 years greater for patients with stage III/IV versus stage I/II disease. Compared to their younger counterparts, older patients with stage III/IV disease were less likely to enter into a GOG treatment protocol. Most common reasons were patient ineligibility (33%), refusal (29%), and investigator decision (20%).ConclusionAge appears to be an important factor influencing treatment selection among patients with stage III/IV ovarian cancer. In addition to reviewing eligibility criteria, practitioners' attitudes should be monitored to assure that elderly patients are not inappropriately denied participation in GOG clinical trials.